Given Imaging Ltd. Supports Fight Against Colorectal Cancer

YOQNEAM, ISRAEL--(Marketwire - March 02, 2012) - Given Imaging Ltd. (NASDAQ: GIVN), a world leader in specialty GI products and pioneer of capsule endoscopy, today announced that the Company will participate in multiple events in honor of National Colorectal Cancer Awareness Month. Throughout the month of March, Given Imaging will be taking part in several national initiatives to raise awareness about colorectal cancer, the third leading cause of cancer-related deaths in the United States, and about the importance of colorectal cancer screening.

Today, Given Imaging employees in the Duluth, Georgia, and Los Angeles, California offices will be dressing in blue to support the Global Colon Cancer Alliance’s Dress in Blue Day. The nationwide program aims to bring attention to colon cancer and to celebrate the courage of those affected by this disease.

“Colorectal cancer affects hundreds of thousands of lives each year and the National Colorectal Cancer Awareness Month is therefore an important initiative that brings attention to the importance of colorectal cancer screening, prevention and research,” said Homi Shamir, president and chief executive officer, Given Imaging Ltd. “We are excited to be engaged in events throughout the month of March to show Given Imaging’s dedication to raising awareness about colorectal cancer.”

Also as a part of National Colorectal Cancer Awareness Month, Given Imaging is proud to be a sponsor of the 2012 Fight Colorectal Cancer’s Call-on Congress. As a sponsor, Given Imaging will be sending a group of employees to Washington D.C. to take part in the three-day event which brings together advocates from across the country to articulate the message that colorectal cancer is preventable, treatable and beatable. Advocates are trained on how to openly discuss this deadly disease with their elected officials and then have the opportunity to speak with members of Congress about the burden of colon cancer, national preventative screening initiatives, and the ongoing need for additional research funding. The final event of the Call-on Congress campaign, the Sixth Annual Advocate Celebration Dinner -- A United Voice Behind a Cure, will take place on Wednesday, March 7, 2012 to celebrate colorectal cancer advocacy and survivorship. For more information on the Call-on Congress campaign, please visit: http://fightcolorectalcancer.org/policy/call-on_congress.

In addition, to raise awareness about the important role family history plays in preventing colorectal cancer, Given Imaging’s employees will be utilizing several exciting new tools from the National Colorectal Cancer Roundtable’s Family PLZ! Campaign. This campaign targets people ages 18 to 45 with a message about understanding family health history, with the goal of increasing screening adherence. The campaign encourages young people to start talking to family members about their family history of colorectal cancer or polyp, spurring young people to take action steps to “search and share their family’s health history,” while reiterating the message that colorectal cancer screening should begin at 50 for those without a family history. For more information on Family PLZ!, please visit: http://familyplz.org/home.

Finally, throughout the month of March, Given Imaging is encouraging all employees to take part in the company’s corporate fundraising initiative. All money raised during the month of March by employees will be donated to the Global Colon Cancer Alliance, the oldest and largest national patient advocacy organization dedicated to ending the suffering caused by colorectal cancer. For more information on the Global Colon Cancer Alliance, please visit: http://www.ccalliance.org/.

Additional information detailing all of Given Imaging’s events during this year’s National Colorectal Cancer Awareness Month can be found on their Facebook page: http://www.facebook.com/GivenImaging.

About Colorectal Cancer

Colorectal cancer remains a potentially fatal disease that generally can be prevented through early detection. Colon cancer occurs in the large intestine (colon), the lower part of the digestive system, while rectal cancer occurs in the last 15-20 centimeters of the colon. Together, they’re often referred to as colorectal cancers.

Colon and rectal cancers begin in the digestive system and develop when cells that line the colon or the rectum become abnormal and grow exponentially. Most cases of colorectal cancer begin as small, non-cancerous (benign) clumps of cells called adenomatous polyps. Only certain kinds of polyps have the potential to become cancerous, and in most people, colorectal cancers develop slowly over a period of several years. In the US alone, more than 51,000 people will die from colorectal cancer in 2010(1).

About Given Imaging Ltd.

Since pioneering the field of capsule endoscopy in 2001, Given Imaging has become a world leader in GI medical devices, offering health care providers a range of innovative options for visualizing, diagnosing and monitoring the digestive system. The company offers a broad product portfolio including PillCam® video capsules for the small bowel, esophagus and colon [PillCam® COLON not approved for use in the United States], industry-leading ManoScan™ high-resolution manometry and Bravo® wireless and Digitrapper® pH and impedance products. Given Imaging is committed to delivering breakthrough innovations to the GI community and supporting its ongoing clinical needs. Given Imaging’s headquarters are located in Yoqneam, Israel, with operating subsidiaries in the United States, Germany, France, Japan, Australia, Vietnam and Hong Kong. For more information, please visit www.givenimaging.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, projections about our business and our future revenues, expenses and profitability. Forward-looking statements may be, but are not necessarily, identified by the use of forward-looking terminology such as “may,” “anticipates,” “estimates,” “expects,” “intends,” “plans,” “believes,” and words and terms of similar substance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual events, results, performance, circumstances or achievements of the Company to be materially different from any future events, results, performance, circumstances or achievements expressed or implied by such forward-looking statements. Factors that could cause actual events, results, performance, circumstances or achievements to differ from such forward-looking statements include, but are not limited to, the following: (1) our ability to develop and bring to market new products, (2) our ability to successfully complete any necessary or required clinical studies with our products, (3) our ability to receive regulatory clearance or approval to market our products or changes in regulatory environment, (4) our success in implementing our sales, marketing and manufacturing plans, (5) the level of adoption of our products by medical practitioners, (6) the emergence of other products that may make our products obsolete, (7) lack of an appropriate bowel preparation materials to be used with our PillCam COLON capsule, (8) protection and validity of patents and other intellectual property rights, (9) the impact of currency exchange rates, (10) the effect of competition by other companies, (11) the outcome of significant litigation, (12) our ability to obtain reimbursement for our product from government and commercial payors, (13) quarterly variations in operating results, (14) the possibility of armed conflict or civil or military unrest in Israel, (15) the impact of global economic conditions, (16) our ability to successfully integrate acquired businesses, (17) changes and reforms in applicable healthcare laws and regulations, (18) quality issues and adverse events related to our products, such as capsule retention, aspiration and failure to attach or detach, bleeding or perforation that could require us to recall products and impact our sales and net income, and (19) other risks and factors disclosed in our filings with the U.S. Securities and Exchange Commission, including, but not limited to, risks and factors identified under such headings as “Risk Factors,” “Cautionary Language Regarding Forward-Looking Statements” and “Operating Results and Financial Review and Prospects” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2010. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except for the Company’s ongoing obligations to disclose material information under the applicable securities laws, it undertakes no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events.

(1) http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-key-statistics